

Ozempic and Rybelsus (semaglutide) coming to prior authorization Nov. 27, 2023



In September we announced that updates to Ozempic and Rybelsus coverage were coming later in the fall.

As of Nov. 27, 2023, Ozempic and Rybelsus will be added to Canada Life's prior authorization drug list and will only be eligible for coverage when used to treat diabetes.

What does this mean for members?

All new requests for coverage of Ozempic or Rybelsus will be subject to prior authorization.

Members will be able to access the Drug Prior Authorization form through the Canada Life website or My Canada Life at Work™.

What does this mean for existing Ozempic or Rybelsus claimers?

Members with other diabetes medications in their history will get ongoing coverage.

Starting in December 2023, we're mailing letters to members taking Ozempic or Rybelsus who don't have other diabetes medication in their history.

Members will have a 70-day grace period from the date of their letter to show that they are using these drugs to treat diabetes. Members using Ozempic or Rybelsus for non-diabetes treatment won't be covered after their grace period.

All members, existing and new, will need to apply for coverage of Ozempic and Rybelsus under their provincial or territorial program, where applicable.